Search

Displaying results 651 - 660 of 841 in total
  1. Drug

    (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide

    go.drugbank.com/drugs/DB08260
    Experimental

    These are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A.

  2. Drug

    (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime

    go.drugbank.com/drugs/DB08553
    Experimental

    (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles.

    Synonyms: (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
  3. Drug

    1D-myo-inositol 1,4,5-trisphosphate

    go.drugbank.com/drugs/DB03401
    Experimental

    Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane.

  4. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil.

  5. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment

  6. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene.

  7. Drug

    ReN001

    go.drugbank.com/drugs/DB05236
    Investigational

    ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans

  8. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  9. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.

  10. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis.